|
|
||||||||
The Annals of Thoracic Surgery, Vol 57, 1211-1216, Copyright © 1994 by The Society of Thoracic Surgeons
MH Staples, RF Dunton, KJ Karlson, HK Leonardi and RL Berger
Heparin resistance, defined as failure of 500 IU per kilogram of body
weight of heparin to prolong the activated clotting time (ACT) to 480
seconds or longer, was noted during 949 of 4,280 (22%) consecutive open
heart surgical procedures performed on adults between 1986 and 1991. The
total population was divided into the following four groups: group 1,
preoperative intraaortic balloon support without concomitant heparin
therapy (n = 138 patients); group 2, preoperative intravenous heparin
therapy (n = 741 patients); group 3, intraaortic balloon support with
concomitant intravenous heparin therapy (n = 137 patients); and group 4,
controls, not receiving preoperatively the therapy given groups 1, 2, or 3
(n = 3,264 patients). The ACT response to an initial dose of 500 IU/kg of
heparin and the incidence of heparin resistance were 596 +/- 203 seconds
and 30% in group 1; 506 +/- 149 seconds and 50% in group 2; 520 +/- 159
seconds and 53% in group 3; and 705 +/- 234 seconds and 14% in group 4,
respectively. These results indicate that preoperative intravenous therapy
and intraaortic balloon support are associated with a decreased ACT
response to intraoperative heparin. Baseline ACT levels and preoperative
platelet counts were not predictive of heparin resistance. A reduced ACT
response to the initial dose of heparin was associated with increased
requirements for supplementary anticoagulant therapy during the ensuing
period on cardiopulmonary bypass, indicating that the decreased sensitivity
to heparin extends beyond the initial episode of heparinization.(ABSTRACT
TRUNCATED AT 250 WORDS)
ARTICLES
Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping
Overholt Division of Cardiothoracic Surgery, New England Deaconess Hospital and Harvard Medical School, Boston, Massachusetts.
This article has been cited by other articles:
![]() |
K. A. Tanaka, N. S. Key, and J. H. Levy Blood Coagulation: Hemostasis and Thrombin Regulation Anesth. Analg., May 1, 2009; 108(5): 1433 - 1446. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Spiess Treating Heparin Resistance With Antithrombin or Fresh Frozen Plasma Ann. Thorac. Surg., June 1, 2008; 85(6): 2153 - 2160. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cooper Jr, J. Abrams, O.H. Frazier, R. Radovancevic, B. Radovancevic, A. W. Bracey, M. J. Kindo, and I. D. Gregoric Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: Possible association with antifibrinolytic therapy J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 963 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Chan, N. C. Hwang, and C. H. Lim A statistical analysis of factors predisposing patients to heparin resistance Perfusion, March 1, 2006; 21(2): 99 - 103. [Abstract] [PDF] |
||||
![]() |
M. Ranucci, G. Isgro, A. Cazzaniga, A. Ditta, A. Boncilli, M. Cotza, G. Carboni, and S. Brozzi Different patterns of heparin resistance: therapeutic implications Perfusion, May 1, 2002; 17(3): 199 - 204. [Abstract] [PDF] |
||||
![]() |
J. H. Lemmer Jr and G. J. Despotis Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery J. Thorac. Cardiovasc. Surg., February 1, 2002; 123(2): 213 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Nicholson, D. M. Keeling, M. E. Sinclair, and R. D. Evans Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass Br. J. Anaesth., December 1, 2001; 87(6): 844 - 847. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vuylsteke, R. J. Mills, A. E. Crosbie, T. I. Burns, and R. D. Latimer Increased pre-operative platelet counts are a possible predictor for reduced sensitivity to heparin Br. J. Anaesth., December 1, 2000; 85(6): 896 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Williams, A. B. D'Ambra, J. R. Beck, T. B. Spanier, D. L.S. Morales, D. N. Helman, and M. C. Oz A randomized trial of antithrombin concentrate for treatment of heparin resistance Ann. Thorac. Surg., September 1, 2000; 70(3): 873 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Levy, F. Montes, F. Szlam, and C. D. Hillyer The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy Anesth. Analg., May 1, 2000; 90(5): 1076 - 1079. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ranucci, G. Isgro, A. Cazzaniga, G. Soro, L. Menicanti, and A. Frigiola Predictors for heparin resistance in patients undergoing coronary artery bypass grafting Perfusion, December 1, 1999; 14(6): 437 - 442. [Abstract] [PDF] |
||||
![]() |
A. S. Weisinger and J. H. Levy Current Hematologic Issues in Cardiac Surgery and Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1998; 2(4): 259 - 271. [Abstract] [PDF] |
||||
![]() |
P. Robbins, M. Forrest, and D. Royston Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 295 - 318. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |